Oculis Shares Rise After Therapy Receives Breakthrough Designation from FDA

Dow Jones

01/06

By Connor Hart

Shares of Oculis climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy designation from the Food and Drug Administration.

The stock rose 13%, to $22.29, in premarket trading Tuesday. Through Monday's close, the stock has gained 8.4% over the past year.

The biopharmaceutical company said that its treatment, Privosegtor, has the potential to become the first neuroprotective therapy for optic neuropathies.

The drug's breakthrough designation is based on results from a recent mid-stage trial that showed the treatment delivered substantial improvement in low-contrast visual acuity, along with consistent anatomical and biological benefits compared with placebo, according to Oculis.

Chief Executive Riad Sherif said the designation underscores the drug's potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis. "Oculis is uniquely positioned to reshape the treatment landscape in areas with substantial unmet needs, and 2026 is shaping up to be a milestone-rich year across our late-stage portfolio," he added.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 06, 2026 06:52 ET (11:52 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2601891218"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601891218\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601891218?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 19:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601891218","market":"us","top_or_hot":-1,"title":"Oculis Shares Rise After Therapy Receives Breakthrough Designation from FDA","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/OCS\">Oculis</a> climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy designation from the Food and Drug Administration. \n</p>\n<p>\n  The stock rose 13%, to $22.29, in premarket trading Tuesday. Through Monday's close, the stock has gained 8.4% over the past year. \n</p>\n<p>\n  The biopharmaceutical company said that its treatment, Privosegtor, has the potential to become the first neuroprotective therapy for optic neuropathies. \n</p>\n<p>\n  The drug's breakthrough designation is based on results from a recent mid-stage trial that showed the treatment delivered substantial improvement in low-contrast visual acuity, along with consistent anatomical and biological benefits compared with placebo, according to Oculis. \n</p>\n<p>\n  Chief Executive Riad Sherif said the designation underscores the drug's potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis. \"Oculis is uniquely positioned to reshape the treatment landscape in areas with substantial unmet needs, and 2026 is shaping up to be a milestone-rich year across our late-stage portfolio,\" he added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2026 06:52 ET (11:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oculis Shares Rise After Therapy Receives Breakthrough Designation from FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOculis Shares Rise After Therapy Receives Breakthrough Designation from FDA\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-06 19:52</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/OCS\">Oculis</a> climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy designation from the Food and Drug Administration. \n</p>\n<p>\n  The stock rose 13%, to $22.29, in premarket trading Tuesday. Through Monday's close, the stock has gained 8.4% over the past year. \n</p>\n<p>\n  The biopharmaceutical company said that its treatment, Privosegtor, has the potential to become the first neuroprotective therapy for optic neuropathies. \n</p>\n<p>\n  The drug's breakthrough designation is based on results from a recent mid-stage trial that showed the treatment delivered substantial improvement in low-contrast visual acuity, along with consistent anatomical and biological benefits compared with placebo, according to Oculis. \n</p>\n<p>\n  Chief Executive Riad Sherif said the designation underscores the drug's potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis. \"Oculis is uniquely positioned to reshape the treatment landscape in areas with substantial unmet needs, and 2026 is shaping up to be a milestone-rich year across our late-stage portfolio,\" he added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2026 06:52 ET (11:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCS","symbol_name":"Oculis","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601891218","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601891218","pubTimestamp":1767700320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Oculis climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy designation from the Food and Drug Administration.The stock rose 13%, to $22.29, in premarket trading Tuesday. Through Monday's close, the stock has gained 8.4% over the past year.The biopharmaceutical company said that its treatment, Privosegtor, has the potential to become the first neuroprotective therapy for optic neuropathies.The drug's breakthrough designation is based on results from a recent mid-stage trial that showed the treatment delivered substantial improvement in low-contrast visual acuity, along with consistent anatomical and biological benefits compared with placebo, according to Oculis.Chief Executive Riad Sherif said the designation underscores the drug's potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis. \"Oculis is uniquely positioned t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCS":"Oculis","BK4007":"制药"},"translate_title":"Oculis疗法获得FDA突破性认定后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCS":1.5},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Oculis climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy designation from the Food and Drug Administration. \n\n\n  The stock rose 13%, to $22.29, in premarket trading Tuesday. Through Monday's close, the stock has gained 8.4% over the past year. \n\n\n  The biopharmaceutical company said that its treatment, Privosegtor, has the potential to become the first neuroprotective therapy for optic neuropathies. \n\n\n  The drug's breakthrough designation is based on results from a recent mid-stage trial that showed the treatment delivered substantial improvement in low-contrast visual acuity, along with consistent anatomical and biological benefits compared with placebo, according to Oculis. \n\n\n  Chief Executive Riad Sherif said the designation underscores the drug's potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis. \"Oculis is uniquely positioned to reshape the treatment landscape in areas with substantial unmet needs, and 2026 is shaping up to be a milestone-rich year across our late-stage portfolio,\" he added. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 06:52 ET (11:52 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}